Moreover, miR-183 has been considered a metastatic inhibitor by targeting ezrin[53] and lymph node metastasis in medullary thyroid carcinoma[54], and this miRNA was recently described as being involved in breast cancer progression[55]. Here, EZR is linked to breast carcinoma.